OBJECTIVES: To assess persistence on SSRIs (most prescribed antidepressants) and associated healthcare costs in a naturalistic setting. METHODS: For this retrospective cohort study based on a US reimbursement claims database, all adults with a claim for a SSRI (citalopram, escitalopram, fluoxetine, paroxetine or sertraline) related to a diagnosis of depression were included. Patients should have had no previous reimbursement for any antidepressant within the previous 6 months. Non-persistence was defined as failing to renew prescription within 30 days in the 6-month period after the index date. RESULTS: In the 45,481 patients included, persistence decreased from 95.5% at 1 month, to 52.6% at 2 months, 37.6% at 3 months and 18.9% at 6 months. Among factors associated with higher 6-month persistence were age 18-34 years, physician's specialty, treatment with escitalopram, absence of abuse history and psychotropic prescription history. During the 6-month after index date, healthcare costs tended to be higher in non-persistent than in persistent patients although not significantly (RR=1.05, adjusted p=0.055). CONCLUSION: Despite some limitations associated with the use of computerized administrative claims data (residual unmeasured confounding), these results highlight a generally low persistence rate at 6 months. Special attention should be given to persistence on treatment, with consideration of potential antidepressant impact.
OBJECTIVES: To assess persistence on SSRIs (most prescribed antidepressants) and associated healthcare costs in a naturalistic setting. METHODS: For this retrospective cohort study based on a US reimbursement claims database, all adults with a claim for a SSRI (citalopram, escitalopram, fluoxetine, paroxetine or sertraline) related to a diagnosis of depression were included. Patients should have had no previous reimbursement for any antidepressant within the previous 6 months. Non-persistence was defined as failing to renew prescription within 30 days in the 6-month period after the index date. RESULTS: In the 45,481 patients included, persistence decreased from 95.5% at 1 month, to 52.6% at 2 months, 37.6% at 3 months and 18.9% at 6 months. Among factors associated with higher 6-month persistence were age 18-34 years, physician's specialty, treatment with escitalopram, absence of abuse history and psychotropic prescription history. During the 6-month after index date, healthcare costs tended to be higher in non-persistent than in persistent patients although not significantly (RR=1.05, adjusted p=0.055). CONCLUSION: Despite some limitations associated with the use of computerized administrative claims data (residual unmeasured confounding), these results highlight a generally low persistence rate at 6 months. Special attention should be given to persistence on treatment, with consideration of potential antidepressant impact.
Authors: Caitlyn T Solem; Ahmed Shelbaya; Yin Wan; Chinmay G Deshpande; Jose Alvir; Elizabeth Pappadopulos Journal: Neuropsychiatr Dis Treat Date: 2016-10-25 Impact factor: 2.570
Authors: Syahrir Zaini; Harvin Anbu Manivanna Bharathy; Ahmad Hatim Sulaiman; Jesjeet Singh Gill; Koh Ong Hui; Hasniza Zaman Huri; Siti Hadijah Shamsudin; Ng Chong Guan Journal: Int J Environ Res Public Health Date: 2018-07-03 Impact factor: 3.390
Authors: Chi-Shin Wu; Alex R Luedtke; Ekaterina Sadikova; Hui-Ju Tsai; Shih-Cheng Liao; Chen-Chung Liu; Susan Shur-Fen Gau; Tyler J VanderWeele; Ronald C Kessler Journal: JAMA Netw Open Date: 2020-02-05